Aloka takes over U.S. sales from Corometrics
Aloka announced last week that it is taking over U.S. distributionof its ultrasound scanners in ob/gyn and veterinary ultrasoundmarkets from Corometrics Medical Systems. The deal supersedesthe previous arrangement between the firms, in which Aloka
Aloka announced last week that it is taking over U.S. distributionof its ultrasound scanners in ob/gyn and veterinary ultrasoundmarkets from Corometrics Medical Systems. The deal supersedesthe previous arrangement between the firms, in which Aloka soldits scanners in radiology and intraoperative markets and Corometricsmaintained exclusive U.S. sales and marketing rights to Alokascanners in the ob/gyn and veterinary markets. Both firms arebased in Wallingford, CT.
The new structure enables the two firms to be more responsiveto customers by allowing each to focus on its core area of expertise-- Aloka in ultrasound and Corometrics in monitoring products-- according to James Pietropaolo, vice president of sales andmarketing. Corometrics will continue to provide service for allAloka ultrasound products in the U.S.
In other Aloka news, the company has announced its MultiViewupgrade for the SSD-2000 ultrasound scanners. The upgrade improvesgray-scale and color Doppler performance and includes a PowerFlowDoppler feature. All SSD-2000 units in the field are upgradableto MultiView and Aloka in August shifted production to new SSD-2000MultiView scanners.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
